The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Flagged first, then by citations
Cited by
Sorted by citations
Items 701–800 of 1,001
Molecularly Targeted Therapies in Oncology: Mechanisms, Resistance, and Combination Strategies
Giercuszkiewicz-Haśnik, K., MORAK-MŁODAWSKA, B. I., & Jeleń, M. (2026) · Molecules · doi:10.3390/molecules31071195 · Cited by 14
BET inhibitors combined with chemotherapy synergistically inhibit the growth of NSCLC cells
Zhou, X. Y., Sun, T., Meng, Y., Luo, J., Chen, J., Xia, B., Zhang, Z., Cheng, Z., & Wang, X. (2021) · Oncology Reports · doi:10.3892/or.2021.8021 · Cited by 13
Targeting IRAK3 for Degradation to Enhance IL-12 Pro-inflammatory Cytokine Production
Rowley, A. M., Brown, B. S., Stofega, M. R., Hoh, H. Y., Mathew, R. S., Marin, V. L., Ding, R., McClure, R. A., Bittencourt, F. M., Chen, J., et al. (2022) · ACS Chemical Biology · doi:10.1021/acschembio.2c00037 · Cited by 13
Nano Proteolysis Targeting Chimeras (PROTACs) with Anti‐Hook Effect for Tumor Therapy
Zhang, N., Hou, D., Hu, X., Liang, J., Wang, M., Song, Z., Li, Y., Wang, Z., An, H., Xu, W., et al. (2023) · Angewandte Chemie · doi:10.1002/ange.202308049 · Cited by 14
Bifunctional Peptide Nanofibrils for Targeted Protein Degradation
Lin, Z., Garcia, B. A., & Lv, D. (2023) · Angewandte Chemie International Edition · doi:10.1002/anie.202316581 · Cited by 13
Pierri, M., Liu, X., Kroupova, A., Rutter, Z. J., Hallatt, A. J., & Ciulli, A. (2024) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2024.129861 · Cited by 13
Self-citationChoi, H.-I., Choi, J., Kim, J. W., Lee, Y. H., Cho, K. H., & Koo, T. (2024) · Molecules · doi:10.3390/molecules29174048 · Cited by 13
Chem-CRISPR/dCas9FCPF: a platform for chemically induced epigenome editing
Altinbay, M., Wang, J., Chen, J., Schäfer, D., Sprang, M., Blagojevic, B., Wölfl, S., Andrade-Navarro, M. A., Đikić, I., Knapp, S., et al. (2024) · Nucleic Acids Research · doi:10.1093/nar/gkae798 · Cited by 14
Proteolysis‐Targeting Chimera (PROTAC): A Revolutionary Tool for Chemical Biology Research
Pan, M., Fu, Z., Hou, H., Yang, C., & Li, J. (2025) · Small Methods · doi:10.1002/smtd.202500402 · Cited by 13
PROTAC: A Novel Technology for Drug Development**
Li, J., & Liu, J. (2020) · ChemistrySelect · doi:10.1002/slct.202003162 · Cited by 13
Chan, A. M., & Fletcher, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00286k · Cited by 13
Liu, L., Shi, L., Wang, Z., Zeng, J., Wang, Y., Xiao, H., & Zhu, Y. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.839857 · Cited by 13
PROTACs: The Future of Leukemia Therapeutics
Anwar, Z., Ali, M. S., Galvano, A., Perez, A., Mantia, M. L., Bukhari, I., & Świątczak, B. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.851087 · Cited by 13
Crystallization of VHL-based PROTAC-induced ternary complexes
Wijaya, A. J., Farnaby, W., & Ciulli, A. (2023) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/bs.mie.2022.10.005 · Cited by 13
Self-citationEngineered PROTAC-CID Systems for Mammalian Inducible Gene Regulation
Ma, D., Yuan, Q., Peng, F., Paredes, V., Zeng, H., Osikpa, E. C., Yang, Q., Peddi, A., Patel, A., Liu, M. S., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09129 · Cited by 14
Recent Advances in the Design and Development of Anticancer Molecules based on PROTAC Technology
Mukhamejanova, Z., Tong, Y., Xiang, Q., Xu, F., & Pang, J. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200312112412 · Cited by 13
Smart PROTACs Enable Controllable Protein Degradation for Precision Cancer Therapy
Chen, L., Wan, X., Shan, X., Zha, W., & Fan, R. (2022) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-022-00586-2 · Cited by 13
Kumar, A., Ali, S., Shen, Q., & Zhou, J. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c02076 · Cited by 14
Native Mass Spectrometry: Insights and Opportunities for Targeted Protein Degradation
Sternicki, L. M., & Poulsen, S. (2023) · Analytical Chemistry · doi:10.1021/acs.analchem.3c03853 · Cited by 12
UBX‐390: A Novel Androgen Receptor Degrader for Therapeutic Intervention in Prostate Cancer
Lee, S., Kim, H.-R., Woo, Y., Kim, J., Kim, H. W., Park, J. Y., Suh, B., Choi, Y.-R., Ahn, J., Ryu, J. H., et al. (2024) · Advanced Science · doi:10.1002/advs.202400398 · Cited by 12
Extrapolating Lessons from Targeted Protein Degradation to Other Proximity-Inducing Drugs
Winter, G. E. (2024) · ACS Chemical Biology · doi:10.1021/acschembio.4c00191 · Cited by 13
A comprehensive primer and review of PROTACs and their In Silico design
Zattoni, J., Vottero, P., Carena, G., Uliveto, C., Pozzati, G., Morabito, B., Gitari, E., Tuszyński, J. A., & Aminpour, M. (2025) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2025.108687 · Cited by 14
Recent advances in PROTAC-based antiviral and antibacterial therapeutics
Zhou, C., Yang, S., Wang, J. J., Pan, W., Yao, H., Li, G., & Niu, M. (2025) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2025.108437 · Cited by 12
Advancing target validation with PROTAC technology
Spitz, M. L., Kashkush, A., & Benhamou, R. I. (2025) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2025.2490248 · Cited by 12
Sternicki, L. M., & Poulsen, S. (2025) · RSC Medicinal Chemistry · doi:10.1039/d5md00617a · Cited by 12
Proteome-Wide Discovery of Degradable Proteins Using Bifunctional Molecules
Forrest, I., Conway, L. P., Gathmann, C., Jadhav, A. M., Chiu, T.-Y., Chaheine, C. M., Estrada, M. A., Shrestha, A., Sarris, K., Reitsma, J. M., et al. (2025) · ACS Central Science · doi:10.1021/acscentsci.5c01594 · Cited by 12
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells
Bouguenina, H., Nicolaou, S., Bihan, Y. L., Bowling, E. A., Calderon, C., Caldwell, J., Harrington, B., Hayes, A., McAndrew, C., Mitsopoulos, C., et al. (2023) · iScience · doi:10.1016/j.isci.2023.107059 · Cited by 12
PROTACs targeting epigenetic proteins
Zhang, C., He, Y., Sun, X., Wei, W., Liu, Y., & Rao, Y. (2023) · Acta Materia Medica · doi:10.15212/amm-2023-0039 · Cited by 13
Cardote, T. A. F., & Ciulli, A. (2017) · ChemMedChem · doi:10.1002/cmdc.201700359 · Cited by 12
Self-citationDaurio, N. A., Zhou, H., Chen, Y., Sheth, P. R., Imbriglio, J. E., McLaren, D. G., Tawa, P., Rachdaoui, N., Previs, M. J., Kasumov, T., et al. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00380 · Cited by 12
Encoding BRAF inhibitor functions in protein degraders
Miller, D. S. J., Voell, S. A., Sosič, I., Proj, M., Rossanese, O. W., Schnakenburg, G., Gütschow, M., Collins, I., & Steinebach, C. (2022) · RSC Medicinal Chemistry · doi:10.1039/d2md00064d · Cited by 12
PROTACting the kinome with covalent warheads
Chatterjee, D. R., Kapoor, S., Jain, M., Das, R., Chowdhury, M. G., & Shard, A. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103417 · Cited by 12
Evolving Rules for Protein Degradation? Insights from the Zinc Finger Degrome
Buhimschi, A. D., & Crews, C. M. (2019) · Biochemistry · doi:10.1021/acs.biochem.8b01307 · Cited by 12
Farrell, B. M., Gerth, F., Yang, C.-H. R., & Yeh, J. T. ‐. (2022) · Genes & Development · doi:10.1101/gad.349717.122 · Cited by 12
Mechanistic insights into a heterobifunctional degrader-induced PTPN2/N1 complex
Hao, Q., Rathinaswamy, M. K., Klinge, K. L., Bratkowski, M. A., Mafi, A., Baumgartner, C. K., Hamel, K. M., Veits, G. K., Jain, R., Catalano, C., et al. (2024) · Communications Chemistry · doi:10.1038/s42004-024-01263-7 · Cited by 11
Crystallizing the Uncrystallizable: Insights from Extensive Screening of PROTACs
Screen, M. A., McCabe, J. F., Askin, S., Guest, J. L., Hodgkinson, P., Cabeza, A. J. C., Blundell, T. J., Rainer, D. N., Coles, S. J., Longcake, A., et al. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07977 · Cited by 11
DNA-based nanostructures for cell membrane receptor regulation and disease treatment
Cheng, Z., Liu, Y., Chen, Q., Man, Y., Man, Y., Zhang, Z., Du, S., Lv, Z., Wang, Q., Shao, K., et al. (2025) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2025.115674 · Cited by 11
Structural basis for DCAF2 as a novel E3 ligase for PROTAC-mediated targeted protein degradation
McMahon, E., Cioffi, A. G., Visperas, P. R., Lin, Y., Shaghafi, M. B., Daczkowski, C. M., Hermann, J. C., Everley, R. A., Neve, R. M., Erlanson, D. A., et al. (2025) · Structure · doi:10.1016/j.str.2025.09.006 · Cited by 11
Ma, L., Xie, L., Wang, Y., Guan, X., Zhang, Y., Guo, H., Zhou, J., Liu, J., Huang, X., He, C., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01111 · Cited by 11
E3 Ubiquitin Ligases: Structures, Biological Functions, Diseases, and Therapy
Wang, H., Peng, J., Li, H., Lan, Y., Guo, J., Qiu, Q., & Huang, X. (2025) · MedComm · doi:10.1002/mco2.70528 · Cited by 13
Biomolecular Condensates as Protein Degradation Tools for Intracellular Targets
Li, Y., Jin, Z., Ahmed, S. U., Das, J., Bleher, R., Chang, D., Yu, X., Flynn, C. D., Zhou, J., Hu, X., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-72967-8 · Cited by 11
eEF2K Inhibitor Design: The Progression of Exemplary Structure-Based Drug Design
Klupt, K. A., & Jia, Z. (2023) · Molecules · doi:10.3390/molecules28031095 · Cited by 11
Huang, Q., Hu, L., Chen, H., Yang, B., Sun, X., & Wang, M. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01802 · Cited by 11
Mainolfi, N., & Rasmusson, T. (2017) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2017.08.005 · Cited by 11
Perspectives on the Development of First-in-Class Protein Degraders
Rambacher, K. M., Calabrese, M. F., & Yamaguchi, M. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0033 · Cited by 11
PROTACs: Novel approach for cancer breakdown by breaking proteins
Memon, H., & Patel, B. M. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120577 · Cited by 11
Dogheim, G. M., & Amralla, M. T. (2023) · Drug Development Research · doi:10.1002/ddr.22055 · Cited by 11
Bifunctional robots inducing targeted protein degradation
Sobhia, M. E., Kumar, H., & Kumari, S. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115384 · Cited by 11
Pharmacological Modulation of Transcriptional Coregulators in Cancer
Bishop, T. R., Zhang, Y., & Erb, M. A. (2019) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2019.04.004 · Cited by 11
Constitutive protein degradation induces acute cell death via proteolysis productsPreprint
Chen, S., Prakash, S., Helgason, E., Gilchrist, C. L., Kenner, L. R., Srinivasan, R., Sterne‐Weiler, T., Hafner, M. A., Piskol, R., Dueber, E. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.06.527237 · Cited by 11
Wang, Y., Deng, S., & Xu, J. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0066 · Cited by 10
Targeting p53 activation: Recent therapeutic advances in cancer and diabetic macular edema
Wang, Z., Zhang, S., Mélita, I. L., & Zhao, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117909 · Cited by 10
Gui, W., Goss, A., & Kodadek, T. J. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c07307 · Cited by 11
Hydrophobic tagging: A promising paradigm for targeted protein degradation
Xin, L., Wang, H., Yang, M., Guo, Z., Zhu, M., Moore, T. W., Dong, C., & Zhou, H. (2025) · Cell Insight · doi:10.1016/j.cellin.2025.100295 · Cited by 10
Discovery and Characterization of PROTACs Targeting Tissue Transglutaminase (TG2)
Valdivia, A., Vagadia, P. P., Guo, G., O’Brien, E., Matei, D. E., & Schiltz, G. E. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01859 · Cited by 10
León, R. G., & Bassham, D. C. (2023) · Pest Management Science · doi:10.1002/ps.7741 · Cited by 10
Castellani, B., Eleuteri, M., Bona, S. D., Cruciani, G., Desantis, J., & Goracci, L. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01144 · Cited by 10
MZ1, a BRD4 inhibitor, exerted its anti-cancer effects by suppressing SDC1 in glioblastoma
Li, G. L., Ma, L., Feng, C., Yin, H., Bao, J., Wu, D., Zhang, Z., Li, X., Li, Z., Yang, C., et al. (2024) · BMC Cancer · doi:10.1186/s12885-024-11966-8 · Cited by 10
A Kinetic Scout Approach Accelerates Targeted Protein Degrader Development
Fan, A. T., Gadbois, G. E., Huang, H., Chaudhry, C., Jiang, J., Sigua, L. H., Smith, E. R., Wu, S., Poirier, G. J., Dunne-Dombrink, K., et al. (2024) · Angewandte Chemie International Edition · doi:10.1002/anie.202417272 · Cited by 10
Maciel, E. V. S., Eisert, J., Müller, J., Habeck, T., & Lermyte, F. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.4c00429 · Cited by 10
Turner, A. W., Bashore, F. M., Falcinelli, S. D., Fox, J. A., Keller, A. L., Fenton, A. D., Geyer, R. F., Allard, B., Kirchherr, J., Archin, N. M., et al. (2025) · Journal of Virology · doi:10.1128/jvi.01777-24 · Cited by 10
Development and Characterization of the First Selective Class IIb Histone Deacetylase Degraders
Zhai, S., Honin, I., Schäker‐Hübner, L., Hanl, M., Jacobi, L., Dressler, F., Pieńkowska, D. E., König, P., Gerhartz, J., Voget, R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00674 · Cited by 10
Walczak, M., Petzold, G., & Thomä, N. H. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2355 · Cited by 10
Gu-liang, Y., Zhong, H., Xia, X., Qi, Z., Wang, C., & Li, S. (2021) · Food Science and Human Wellness · doi:10.1016/j.fshw.2021.11.001 · Cited by 10
Progress on Small-Molecule Proteolysis-Targeting Chimeras
Huang, W., Wang, B., Zhang, Z., Zhang, C., Zeng, S., & Shen, Z. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0161 · Cited by 10
Harmony of Protein Tags and Chimeric Molecules Empowers Targeted Protein Ubiquitination and Beyond
Lawer, A., Schulz, L. P., Sawyer, R. C., & Liu, X. (2024) · Cells · doi:10.3390/cells13050426 · Cited by 9
TRIM25: A Global Player of Cell Death Pathways and Promising Target of Tumor-Sensitizing Therapies
Eberhardt, W., Nasrullah, U., & Pfeilschifter, J. M. (2025) · Cells · doi:10.3390/cells14020065 · Cited by 9
Peng, X., Tan, X., Zhang, H., Gao, S. W., & Zhang, J. (2025) · ChemBioChem · doi:10.1002/cbic.202400900 · Cited by 9
Uemoto, Y., Lin, C.-C. A., Wang, B., Ye, D., Fang, Y. V., Bikorimana, E., Napolitano, F., Chica-Parrado, M. D. R., Li, C. I., Mendiratta, S., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217668 · Cited by 9
Pioneering protein degradation for agricultural applications
Morgan, G. L., Dickson, H., Ford, B., Noras, A., Bremmer, S. C., Watts, B. E., Pilotte, J. R., Anderson, E., Sullivan, E. D., Stoner, M., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08013-y · Cited by 9
Kashyap, D., Haider, S. M., Milne, T. A., & Booth, M. J. (2025) · JACS Au · doi:10.1021/jacsau.5c00422 · Cited by 9
Opportunities in proximity modulation: Bridging academia and industry
Đikić, I., Mayor‐Ruiz, C., Winter, G. E., Koch, K., Ciulli, A., & Thomä, N. H. (2025) · Molecular Cell · doi:10.1016/j.molcel.2025.07.018 · Cited by 10
Self-citationElucidating biased signaling in class A GPCRs
Xu, N., Legall, E., Johnson, R. H., Zhu, L., & Liu, W. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.10.008 · Cited by 9
Zhao, Q., Zeng, R., Bi, T., Yang, X., Wang, T., Chen, L., Huang, J., Dai, X., Xu, H., Sun, Q., et al. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c18202 · Cited by 9
Inganäs, E., Lavén, H., Caraballo, R., Klingegård, F., Eklund, M., Andersson, L., Hilgendorf, C., & Matsson, P. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c01499 · Cited by 9
Design of Class I/IV Bromodomain-Targeting Degraders for Chromatin Remodeling Complexes
Zahid, H., Costello, J. P., Li, Y., Kimbrough, J. R., Actis, M., Ranković, Z., Yan, Q., & Pomerantz, W. C. K. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00902 · Cited by 9
Native mass spectrometry interrogation of complexes formed during targeted protein degradation
Ahmed, I. M. M., & Beveridge, R. (2023) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.9604 · Cited by 9
The 17 th EFMC Short Course on Medicinal Chemistry on Small Molecule Protein Degraders
Ciulli, A., O’Connor, S., Chung, C., Hartung, I. V., Testa, A., Daniels, D. L., & Heitman, L. H. (2023) · ChemMedChem · doi:10.1002/cmdc.202300464 · Cited by 9
Self-citationSynthesis, SAR, and application of JQ1 analogs as PROTACs for cancer therapy
De, S., Sahu, R., Palei, S., & Nanda, L. N. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117875 · Cited by 9
Proteolysis targeting chimera of BI-2536 induces potent dual degradation of PLK1 and BET proteins
Song, S., Yang, W., & Tai, W. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118087 · Cited by 9
Yang, X., He, Y., Kim, R. D., Fleming, J. B., & Xie, H. (2020) · Targeted Oncology · doi:10.1007/s11523-020-00782-2 · Cited by 10
Reboud‐Ravaux, M. (2021) · Biologie Aujourd hui · doi:10.1051/jbio/2021007 · Cited by 10
Palomba, T., Tassone, G., Vacca, C., Bartalucci, M., Valeri, A., Pozzi, C., Cross, S., Siragusa, L., & Desantis, J. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232214218 · Cited by 9
Apprato, G., D’Agostini, G., Rossetti, P., Ermondi, G., & Caron, G. (2023) · Molecules · doi:10.3390/molecules28031206 · Cited by 9
Kang, J. H., Splinter, P. L., Trussoni, C. E., Pirius, N., Gores, G. J., LaRusso, N. F., & O’Hara, S. P. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.03.235 · Cited by 9
Song, Y., Wu, S., Shen, Z., Zhao, D., Chan, T. S. Y., Huang, H., Qiu, L., Li, J., Tan, T., Zhu, J., et al. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00448-5 · Cited by 9
Zhang, J., Zhang, X., Huang, H., & Ding, Y. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.104318 · Cited by 9
Main methods and tools for peptide development based on protein-protein interactions (PPIs)
Baeza, J., Bedoya, M., Cruz, P., Ojeda, P., Adasme-Carreño, F., Cerda, O., & González, W. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.151623 · Cited by 8
Peng, R., Liu, X., Chen, C., Guo, R., & Min, J. (2024) · RSC Medicinal Chemistry · doi:10.1039/d4md00961d · Cited by 8
Chen, S., Solazzo, R., Fouché, M., ROTH, H. ‐., Dittrich, B., & Riniker, S. (2025) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.5c00736 · Cited by 8
Engineering brain-penetrant PROTACs: Bridging molecular design and CNS delivery
Li, X., Li, J., Sun, Y., Yao, T., Lu, Y., Liu, S., Li, H., Shi, Y., Chen, L., Zhao, Y., et al. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115876 · Cited by 8
Kou, X., Li, W., Pan, F., Huang, X., Meng, Q., Zhang, Y., & Ke, Q. (2024) · Food Hydrocolloids · doi:10.1016/j.foodhyd.2024.110380 · Cited by 8
Liu, N., Wang, S., Li, M., Zhao, N., Wang, D., Zhang, R., Yu, M., Zhao, L., Zhang, S., Han, F., et al. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107377 · Cited by 8
Huang, C., Harris, C. L., Siddiqui, G., & Jörg, M. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00726 · Cited by 8
Novel gene mutation in von Hippel-Lindau disease – a report of two cases
Wang, R., Cao, W., Wang, Z., & Zhu, H. (2019) · BMC Medical Genetics · doi:10.1186/s12881-019-0930-8 · Cited by 8
Yang, Y., Wu, Z., Chen, P., Zheng, P., Zhang, H., & Zhou, J. (2020) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0264 · Cited by 8
Li, Q., Huang, Y., Xu, J., Mao, F., Zhou, B. O., Sun, L., Basinski, B. W., Aksu, M., Liu, J., Dou, Y., et al. (2021) · Stem Cell Reports · doi:10.1016/j.stemcr.2021.10.002 · Cited by 8
Development of a PDEδ‐Targeting PROTACs that Impair Lipid Metabolism
Winzker, M., Friese, A., Koch, U., Janning, P., Ziegler, S., & Waldmann, H. (2019) · Angewandte Chemie · doi:10.1002/ange.201913904 · Cited by 8
Synthetic approaches to constructing proteolysis targeting chimeras (PROTACs)
Bakulina, O., Sapegin, A., Bunev, A. S., & Krasavin, M. (2022) · Mendeleev Communications · doi:10.1016/j.mencom.2022.07.001 · Cited by 8
PROTAC: A Novel Drug Delivery Technology for Targeting Proteins in Cancer Cells
Bala, R., Sindhu, R. K., Madaan, R., & Yadav, S. K. (2022) · Current Drug Discovery Technologies · doi:10.2174/1570163820666221031124612 · Cited by 8
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
